Today: 14 May 2026
Nike stock today: NKE slips after hours as 2026 trading starts — what to watch next
3 January 2026
1 min read

Nike stock today: NKE slips after hours as 2026 trading starts — what to watch next

New York, Jan 2, 2026, 19:27 ET — After-hours

  • Nike shares eased on the first trading day of 2026, lagging a mixed tape for consumer names.
  • Traders remain focused on signs the company can steady margins and demand without heavy discounting.

Nike shares dipped 0.7% on Friday and were flat in after-hours trading — the electronic session after the 4 p.m. close — at $63.28. The stock traded between $62.58 and $64.18 in the session, with about 22.3 million shares changing hands.

The move matters because Nike has been trying to convince investors that a brand and distribution reset can lift demand without dragging profitability lower. The stock’s 52-week range underscores how sensitive that debate has been, with shares having traded between $52.28 and $82.44.

Nike’s latest quarterly filing showed why the market is still keyed to margins. Gross margin fell 300 basis points — 3 percentage points — to 40.6% in the quarter ended Nov. 30, hurt mainly by higher product costs including tariffs in North America and a lower average selling price linked to discounts and channel mix, the filing showed.

U.S. stocks ended mixed in the first session of 2026, with the Dow closing up 0.66% and the S&P 500 up 0.19%, while the Nasdaq slipped 0.03% as chip stocks led and some consumer shares lagged, according to Reuters. “‘Buy the dip, sell the rip,’” said Joe Mazzola, head of trading and derivatives strategist at Charles Schwab, pointing to a short-term trading mindset in the market. Reuters

Other athletic and apparel names outperformed Nike on Friday. Under Armour’s UA shares rose 5.4% and its UAA shares gained 6.4%, while Deckers Outdoor — parent of Hoka — climbed 3.0% and Lululemon added 1.4%.

Nike-specific headlines were limited on Friday, leaving the stock to trade more in line with broader risk appetite and positioning into the new year. Investors have been quick to fade rallies and buy pullbacks in large consumer brands as they handicap the pace of rate cuts and the durability of demand.

Insider activity has also stayed on traders’ radar. A Form 4 — the SEC document insiders use to disclose stock transactions — showed CEO Elliott Hill bought 16,388 Nike Class B shares at a weighted-average $61.10 on Dec. 29, taking his directly held stake to 241,587 shares.

Even so, the purchase does not change the near-term pressure points for Nike: clearing product without deeper markdowns, stabilizing digital traffic, and rebuilding momentum in Greater China. Those factors have mattered more than one-off signals in recent months.

The next clear checkpoint is Nike’s next earnings report. The company is listed to report results on March 19, 2026, according to Yahoo Finance’s earnings calendar.

Between now and then, traders will be watching for any fresh read-throughs on U.S. consumer spending and freight-and-tariff costs that can move margin expectations. For Nike, that usually shows up in how quickly inventories normalize and whether wholesale growth can offset softness in its direct business.

Stock Market Today

  • Nurix Therapeutics Stock: Is Its Premium 23.3x Price-to-Sales Multiple Justified?
    May 14, 2026, 9:02 AM EDT. Nurix Therapeutics (NRIX) shares rose 1.38% to $16.18 amid mixed recent performance, down 10% year to date but up nearly 69% over one year. The stock trades at a high price-to-sales (P/S) multiple of 23.3x, well above the US biotech average of 9.7x. This premium reflects strong analyst revenue growth forecasts of 42.2% annually, outpacing the broader market. However, Nurix remains loss-making with $295 million in ongoing losses and a $1.65 billion market cap, making it vulnerable to clinical setbacks. Investors should weigh the high growth potential against risks in this early-stage biotech before assuming the premium valuation is sustainable.

Latest articles

Apple Backs Google in EU AI Fight as iPhone Rules Loom

Apple Backs Google in EU AI Fight as iPhone Rules Loom

14 May 2026
Apple warned the European Commission that proposed EU rules forcing Google’s Android to open core features to rival AI assistants could endanger privacy, security, and device performance. The Commission’s feedback period closed Wednesday, with a final decision expected by July 27. Apple argued the measures could set a precedent for its own platforms. Google also opposes the plan, calling it an “unwarranted intervention.”
Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

14 May 2026
Precigen shares jumped 14.1% in early trading after first-quarter revenue reached $23.3 million, beating estimates, and net loss narrowed to $7.9 million from $54.2 million a year earlier. Papzimeos, its new RRP therapy, generated $21.6 million in net product revenue. The company ended March with $56.7 million in cash and expects current funds and Papzimeos sales to last through 2026.
POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

14 May 2026
POET Technologies signed a supply and joint-development agreement with Lumilens, including a $50 million initial order for optical engines used in AI data-center networks. The companies said cumulative purchases could exceed $500 million over five years. POET shares rose 16% after the news. First engineering samples are expected in late 2026, with production targeted for 2027.
AST SpaceMobile stock jumps nearly 15% as BlueBird 6 milestone puts 2026 rollout back in focus
Previous Story

AST SpaceMobile stock jumps nearly 15% as BlueBird 6 milestone puts 2026 rollout back in focus

NASA’s Artemis II Moon mission is getting closer — latest on the 2026 launch window
Next Story

NASA’s Artemis II Moon mission is getting closer — latest on the 2026 launch window

Go toTop